Gene Therapy Start-Up Audentes Emerges With $30M Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
Three venture firms back a San Francisco start-up studying gene therapies for rare muscle disorders. The funding is the latest sign that VCs are warming up to a field once regarded as overly risky.